New hope for Tough-to-Treat throat cancer patients
NCT ID NCT07496190
Summary
This study is testing a new drug called becotatug vedotin for people with advanced nasopharyngeal cancer (a type of throat cancer) whose cancer doesn't shrink enough after initial chemo-immunotherapy. The goal is to see if adding this drug during radiation and follow-up treatment can help patients live longer without their cancer getting worse. It's a Phase 2 trial for 59 patients who meet specific health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.